Strategies and challenges of toxicity reduction in nasopharyngeal carcinoma in the era of precision radiotherapy: from paradigm shift to integrated decision-making.

In the era of intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) for nasopharyngeal carcinoma (NPC), local control rates have improved significantly, with 5-year local control rates now exceeding 90% for locally advanced disease. This progress has shifted the treatment focus from "ensuring survival" to "optimizing quality of survival." Treatment-related acute and chronic toxicities are now recognized as major constraints on patients' long-term quality of life. This review systematically summarizes and synthesizes the latest evidence on toxicity reduction through a three-dimensional strategy: spatial precision sculpting, temporal sequential optimization, and energy technology escalation. We critically examine the underlying logic, clinical implementation challenges, and ongoing controversies associated with each dimension, and explore their interdependence in clinical decision-making. Although much of the key evidence originates from large-scale clinical trials in high-incidence regions, the resulting principles are increasingly shaping global practice. For example, international guidelines now recommend target volume reduction based on tumor response to induction chemotherapy. However, this approach depends heavily on precise imaging and consistent contouring. Other developments include sequential chemoradiotherapy and chemotherapy de-escalation combined with immunotherapy, which challenge traditional standards but also raise new questions about patient selection and toxicity profiles. Meanwhile, proton therapy offers physical advantages but still lacks Phase III survival evidence and faces cost-effectiveness debates. The review concludes that successful toxicity reduction will require an individualized, integrated decision-making system. This system should incorporate multidimensional biomarkers, standardized patient-reported outcomes (PROs), and global real-world data, potentially synthesized by artificial intelligence (AI)-driven platforms to navigate the complex trade-offs between efficacy and toxicity. The goal is to move beyond "disease cure" toward value-based medicine focused on holistic recovery.